Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Erythropoetin (ausschließlich Epoetin alfa und zeta), ATC B03XA01 für die Zeit 01.07.2026 - 30.06.2028

Section 130a, Paragraph 8 of the German Social Code Book V (SGB V) allows health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the German Act Against Restraints of Competition (GWB) is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, relating to the aforementioned active substance Erythropoetin (exclusively Epoetin alfa and zeta), ATC B03XA01, DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the approval model for the aforementioned active substance will come into force for the first time on 01.07.2026 and will end on 30.06.2028. It will end automatically, regardless of this, with the entry into force of the exclusive contract.